Larimar Therapeutics, Inc.
HealthcareNASDAQ:LRMR · NASDAQ Global Market
-$0.13 today
Vol 1.56M · Avg 2.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-212.2%
avg 240.7%
ROIC
-210.0%
avg 294.2%
ROA
-113.6%
avg -86.6%
Analysis
ROA is currently the strongest return metric at -113.6% versus its period average of -86.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Carole S. Ben-Maimon | Chief Executive Officer, President & Director | $976,403.00 | — | 67 | $600,600.00 | 0.70% |
Michael Celano | Secretary & Chief Financial Officer | $696,996.00 | — | 67 | $225,622.00 | 0.26% |
Gopi Shankar | Chief Development Officer | $642,351.00 | — | 55 | $153,822.00 | 0.18% |
Russell G. Clayton | Chief Medical Officer | — | — | 65 | $153,822.00 | 0.18% |
Francis Michael Conway | Vice President & Controller | — | — | — | $225,622.00 | 0.26% |
John Berman | Vice President of Finance & Administration | — | — | — | $27,000.00 | 0.03% |
Jennifer Spokes Johansson | Vice President of Legal & Compliance | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$55.55M
Sells
0
$0.00
Net Sentiment
+$55.55M
Net buying
Most Active
Flynn James E
7 transactions
Analysis
Insiders reported 10 buys worth $55.55M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $55.55M. Flynn James E was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages LRMR?
Larimar Therapeutics, Inc. (LRMR) lists 7 active executives. The top listed executive is Carole S. Ben-Maimon, Chief Executive Officer, President & Director.
Are LRMR insiders buying or selling?
Recent insider activity shows net buying of $188.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.